Adaptive Biotechnology (MSFT & Genentech partner)"Microsoft and Adaptive Biotechnologies announce partnership using AI to decode immune system; diagnose, treat disease"
They also have a partnership with Genentech (January 2019)
ADPT - Adaptive Biotechnology
IPO: June 27th 2019 - open @$39 (above current price)
Vision: We aim to improve people’s lives by translating the scale and precision of their adaptive immune systems into products to help diagnose, treat, and monitor disease.
Great risk reward with an entry right now. If we break the IPO low @36.2, I would recommend exiting part of your position.
Happy trading!
dorfmanmaster
P.S:
I think this is a short-term, not to mention long-term good investment.
I recommend looking for their research on cellular therapy.
